Proposal for a Kava Quality Standardization Code

被引:53
作者
Teschke, Rolf [1 ]
Lebot, Vincent [2 ]
机构
[1] Goethe Univ Frankfurt, Teaching Hosp, Klinikum Hanau, Dept Internal Med 2,Div Gastroenterol & Hepatol, D-63450 Hanau, Germany
[2] CIRAD, Port Vila, Vanuatu
关键词
Kava hepatotoxicity; Kava; Piper methysticum; kava quality; kava quality standardization; PIPER-METHYSTICUM; BOTANICAL ROOTS; ARNHEM-LAND; HEPATOTOXICITY; EXTRACTS; SAFETY; HEPATITIS; TOXICITY; IDENTIFICATION; CHEMOTYPES;
D O I
10.1016/j.fct.2011.06.075
中图分类号
TS2 [食品工业];
学科分类号
100403 [营养与食品卫生学];
摘要
Rare cases of hepatotoxicity emerged with the use of kava drugs and dietary supplements prepared from rhizomes and roots of the South Pacific plant kava (Piper methysticum). Their psychoactive, anxiolytic, relaxing, and recreational ingredients are the kavalactones kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin, but there is little evidence that these kavalactones or the non-kavalactones pipermethystine and flavokavain B are the culprits of the adverse hepatic reactions. It rather appears that poor quality of the kava material was responsible for the liver toxicity. Analysis of existing kava quality standardizations with focus on chemical, agricultural, manufacturing, nutritional, regulatory, and legislation backgrounds showed major shortcomings that could easily explain quality problems. We therefore suggest a uniform, internationally accepted device for kava quality standardizations that are in the interest of the consumers because of safety reasons and will meet the expectations of kava farmers, pharmaceutical manufacturers, regulators of agencies, and legislators. The initial step resides in the establishment of Pan-Pacific kava quality legislation as an important part of the propmed Kava Quality Standardization Code. In conclusion, a sophisticated approach to establish kava quality standardizations is needed for safe human use of kava as relaxing traditional beverages, the anxiolytic drugs, and recreational dietary supplements. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2503 / 2516
页数:14
相关论文
共 92 条
[1]
Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.) [J].
Anke, J ;
Ramzan, I .
JOURNAL OF ETHNOPHARMACOLOGY, 2004, 93 (2-3) :153-160
[2]
Kava hepatotoxicity: Are we any closer to the truth? [J].
Anke, J ;
Ramzan, I .
PLANTA MEDICA, 2004, 70 (03) :193-196
[3]
[Anonymous], 2003, Cochrane Database Syst. Rev, DOI DOI 10.1002/14651858.CD003383
[4]
[Anonymous], 2007, ASS RISK HEP KAV PRO
[5]
Applequist WL, 2006, NOVON, V16, P3, DOI 10.3417/1055-3177(2006)16[3:VOPMVW]2.0.CO
[6]
2
[7]
BfArM. Bundesinstitut fur Arzneimittel und Medizinprodukte Bonn. Federal Institute for Drugs and Medicinal Products in Germany, 2002, REJ DRUG RISKS STEP
[8]
Bone K, 2005, ESSENTIAL GUIDE HERB, P155
[9]
Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii [J].
Brown, Amy C. .
CLINICAL TOXICOLOGY, 2007, 45 (05) :549-556
[10]
Kava kava: examining new reports of toxicity [J].
Clouatre, DL .
TOXICOLOGY LETTERS, 2004, 150 (01) :85-96